Implications of Key Trials in Advanced Nonsmall Cell Lung CancerBONOMI, Philip D.Cancer. 2010, Vol 116, Num 5, pp 1155-1164, issn 0008-543X, 10 p.Article

Novel treatments in non-small cell lung cancerLESLIE, William T; BONOMI, Philip D.Hematology/oncology clinics of North America. 2004, Vol 18, Num 1, issn 0889-8588, xiii, 245-267 [24 p.]Article

Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancerBONOMI, Philip D.American journal of health-system pharmacy. 2003, Vol 60, pp S16-S21, issn 1079-2082, SUP9Conference Paper

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancerJÄNNE, Pasi A; VON PAWEL, Joachim; DASSE, Kathy et al.Journal of clinical oncology. 2007, Vol 25, Num 25, pp 3936-3944, issn 0732-183X, 9 p.Article

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung CancerHEYMACH, John V; PAZ-ARES, Luis; BONOMI, Philip D et al.Journal of clinical oncology. 2008, Vol 26, Num 33, pp 5407-5415, issn 0732-183X, 9 p.Article

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non―Small-Cell Lung CancerPATEL, Jyoti D; HENSING, Thomas A; RADEMAKER, Alfred et al.Journal of clinical oncology. 2009, Vol 27, Num 20, pp 3284-3289, issn 0732-183X, 6 p.Article

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. DiscussionBONOMI, Philip D; BUCKINGHAM, Lela; SEQUIST, Lecia et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4606s-4612s, 2Conference Paper

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerRUDIN, Charles M; HANN, Christine L; RANSON, Malcolm R et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3163-3169, issn 1078-0432, 7 p.Article

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancerHERBST, Roy S; O'NEILL, Vincent J; FEHRENBACHER, Louis et al.Journal of clinical oncology. 2007, Vol 25, Num 30, pp 4743-4750, issn 0732-183X, 8 p.Article

Novel agents in the treatment of lung cancer : Fourth cambridge conferenceLYNCH, Thomas J; BONOMI, Philip D; PEREZ-SOLER, Roman et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4583s-4586s, 2Conference Paper